COMPARISON BETWEEN FOUR DIFFERENT TREATMENT REGIMENS AFTER CORNEAL CROSS LINKING FOR THE MANAGEMENT OF KERATOCONUS | ||
| ALEXMED ePosters | ||
| Article 1, Volume 5, Issue 1, January 2023, Pages 22-23 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2023.193386.1559 | ||
| Authors | ||
| Ahmed Abdelkareem Elmassry1; Mahmoud Hassan Morsi1; Ehab Osman2; Ahmed Mohamed Hassan Eweidah* 1 | ||
| 1Department of Ophthalmology, Faculty of Medicine, Alexandria University | ||
| 2Department of ophthalmology, Faculty of Medicine, Alexandria University | ||
| Abstract | ||
| Keratoconus (KC) is one of the most prevalent corneal ectatic disorders characterized by progressive, non-inflammatory changes in stromal collagen structure and usually results in protrusion and alteration of the central and paracentral cornea. Treatment of early keratoconus involves prescribing spectacles, rigid gas permeable contact lenses. In a small but significant proportion of patients, disease progression may require eventual corneal transplantation. Several new therapeutic options have emerged, including refractive, optical, and lamellar surgery, which slow the progression of the disease and/or delay more intensive treatment. Corneal collagen crosslinking (CXL) with ultraviolet A (UV-A) light and riboflavin (vitamin B2) is a relatively new treatment that reportedly slows the advancement of the disease in its early stages. The focus of postoperative management after corneal crosslinking is to restore a healthy ocular surface as quickly as possible. There are three main aspects to post-crosslinking patient management: 1) hastening reepithelialization, 2) preventing infection, and 3) reducing pain. | ||
| Keywords | ||
| Keratoconus (KC); crosslinking (CXL); corneal ectatic disorders | ||
|
Supplementary Files
|
||
|
Statistics Article View: 96 |
||
